Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

NorthX Biologics Matfors AB

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Galderma

Anna Törner: “My quantified life”

“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

ZEISS Connected Quality: One metrology hub

The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.

Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Explore 3D Testing of Deformation and Motions

Powerful measurement capabilities with the new ZEISS ARAMIS 1.

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Björn Arvidsson: ”We must raise our gaze to find the answers of the future”

A system approach isn't just about understanding complexity – it's about making better decisions. By seeing ourselves as part of larger systems, we can better a...

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Bakslag i USA får Elicera att ändra patentstrategi

Car T-bolaget Elicera har fått avslag på en patentansökan i USA för sin Itank-plattform – men uppger sig nu ha tagit fram en ny strategi för att ändå nå patentskydd.

Abbvie ryktas överväga miljardförvärv inom mental hälsa

Läkemedelsbolaget Abbvie uppges föra diskussioner om att förvärva Gilgamesh Pharmaceuticals, ett bolag inom mental hälsa, i en affär som ska ligga på omkring en miljard dollar.

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Smartzoom 100 – The New Digital Microscope for Maximum Efficiency

Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...